WASHINGTON — The drug industry is quietly troubled over Donald Trump’s tough talk on trade.
The Republican presidential nominee has promised to aggressively renegotiate America’s trade deals — and to tear them up if need be. Those pledges are now rankling a biopharmaceutical sector that depends heavily on the deals to protect their intellectual property and, by extension, their entire business model.
Provisions in the deals typically require participating nations to adhere to patent protections similar to those in the United States, to give companies relief if there is a delay in granting a patent, and to keep their clinical data confidential.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect